Pfizer. has filed a patent for a chemically and physically stable topical formulation that can be used to treat inflammatory disorders. The formulation contains a specific compound called (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, along with other ingredients such as hexylene glycol, white petrolatum, mono- and di-glycerides, and paraffin wax. The formulation is free of butylated hydroxytoluene and has a low degradant diol content. GlobalData’s report on Pfizer gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Pfizer, Cancer treatment biomarkers was a key innovation area identified from patents. Pfizer's grant share as of September 2023 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Topical formulation for treating inflammatory disorders
A recently filed patent (Publication Number: US20230310472A1) describes a topical formulation for the treatment of various skin conditions. The formulation includes a specific compound, (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, or a pharmaceutically acceptable salt thereof, in a concentration ranging from 0.0025% to 2%. The formulation also contains hexylene glycol, mono- and di-glycerides, paraffin wax, and white petrolatum. Importantly, the formulation is free of butylated hydroxytoluene, a common additive in skincare products. Additionally, the formulation has a low level of degradant diol, which is a measure of stability, at 0 to 6 months at temperatures between 5°C and 40°C.
The patent also claims a specific composition of the topical formulation, which includes 5% hexylene glycol, 7% mono- and diglycerides, and 5% paraffin wax. This composition may provide optimal efficacy for the treatment of skin conditions.
Furthermore, the patent describes a method for treating various diseases and conditions, including psoriasis, eczema, dermatitis, alopecia areata, vitiligo, acne, and many others. The method involves administering the topical formulation to individuals in need of treatment. The formulation, as described in the patent, is effective for the treatment of psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, erythrodermic psoriasis, and inverse psoriasis. It is also effective for the treatment of eczema, atopic dermatitis, hand dermatitis, contact dermatitis, and various other skin conditions.
Overall, this patent presents a novel topical formulation for the treatment of a wide range of skin conditions. The formulation contains specific ingredients and concentrations, and it is free of certain additives that may cause adverse effects. The method described in the patent provides a promising approach for the treatment of psoriasis, eczema, and other dermatological conditions.
To know more about GlobalData’s detailed insights on Pfizer, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
